

George W. Bush Presidential Library

Collection: Executive Clerk, Office of the

Series: Saunders, G. Timothy (Tim) - Bill Files

Folder Title: 05/14/2002 [S. 1094] [771213]

LAW_M

771213

FG006-01

Barcode Scanning Sheet

Collection Code: **SECLOG**

Staff Name:

Document Date:

Correspondent: **TIM SAUNDERS**

Subject/Description: **OVERSIZE ATTACHMENT # 9465 NARA # 9356 BOX 1
FOLDER 21B BILL FILE RECEIVED FROM THE OFFICE OF
THE EXECUTIVE CLERK - MAY 14 02 ENROLLED BILL S.
1094 ☐ HEMATOLOGICAL CANCER RESEARCH
INVESTMENT AND EDUCATION ACT OF 2002**



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D. C. 20503

THE PRESIDENT HAS SEEN

5.14.02

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget	Approval
Department of Health and Human Services	Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures

One Hundred Seventh Congress of the United States of America

AT THE SECOND SESSION

*Begun and held at the City of Washington on Wednesday,
the twenty-third day of January, two thousand and two*

An Act

To amend the Public Health Service Act to provide for research, information, and education with respect to blood cancer.

*Be it enacted by the Senate and House of Representatives of
the United States of America in Congress assembled,*

SECTION 1. SHORT TITLE.

This Act may be cited as the "Hematological Cancer Research Investment and Education Act of 2002".

SEC. 2. FINDINGS.

Congress finds that:

(1) An estimated 109,500 people in the United States will be diagnosed with leukemia, lymphoma, and multiple myeloma in 2001.

(2) New cases of the blood cancers described in paragraph (1) account for 8.6 percent of new cancer cases.

(3) Those devastating blood cancers will cause the deaths of an estimated 60,300 persons in the United States in 2001. Every 9 minutes, a person in the United States dies from leukemia, lymphoma, or multiple myeloma.

(4) While less than 5 percent of Federal funds for cancer research are spent on those blood cancers, those blood cancers cause 11 percent of all cancer deaths in the United States.

(5) Increased Federal support of research into leukemia, lymphoma, and multiple myeloma has resulted and will continue to result in significant advances in the treatment, and ultimately the cure, of those blood cancers as well as other cancers.

SEC. 3. RESEARCH, INFORMATION, AND EDUCATION WITH RESPECT TO BLOOD CANCER.

Part C of title IV of the Public Health Service Act (42 U.S.C. 285 et seq.) is amended by inserting after section 419C the following:

"SEC. 417D. RESEARCH, INFORMATION, AND EDUCATION WITH RESPECT TO BLOOD CANCER.

"(a) JOE MOAKLEY RESEARCH EXCELLENCE PROGRAM.—

"(1) IN GENERAL.—The Director of NIH shall expand, intensify, and coordinate programs for the conduct and support of research with respect to blood cancer, and particularly with respect to leukemia, lymphoma, and multiple myeloma.

"(2) ADMINISTRATION.—The Director of NIH shall carry out this subsection through the Director of the National Cancer Institute and in collaboration with any other agencies that the Director determines to be appropriate.


"(3) AUTHORIZATION OF APPROPRIATIONS.—For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose.

"(b) GERALDINE FERRARO CANCER EDUCATION PROGRAM.—


"(1) IN GENERAL.—The Secretary shall direct the appropriate agency within the Department of Health and Human Services, in collaboration with the Director of NIH, to establish and carry out a program to provide information and education for patients and the general public with respect to blood cancer, and particularly with respect to the treatment of leukemia, lymphoma, and multiple myeloma.

"(2) ADMINISTRATION.—The Agency determined by the Secretary under paragraph (1) shall carry out this subsection in collaboration with private health organizations that have national education and patient assistance programs on blood-related cancers.

"(3) AUTHORIZATION OF APPROPRIATIONS.—For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose."




Speaker of the House of Representatives.




*Vice President of the United States and
President of the Senate Pro Tempore.*

APPROVED

MAY 14 2002



ORM
Scanning insert sheet



Remainder of case not scanned



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell E. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".

The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,

A handwritten signature in cursive script, reading "Tommy G. Thompson", is written over a horizontal line.

Tommy G. Thompson

David E. Kalbaugh

05/14/2002 10:18:53 AM

Record Type: Record

To: Sherman A. Williams/WHO/EOP@EOP, Wanda M. Evans/WHO/EOP@EOP

cc:

Subject: EVENT BACKGROUNDER: SIGNING OF HEMATOLOGICAL CANCER RESEARCH INVESTMENT AND EDUCATION ACT

Make sure that this information is noted in the bill record. Meaning - signed in Oval Office ceremony with members of Congress and other guests etc. Thanks

----- Forwarded by David E. Kalbaugh/WHO/EOP on 05/14/2002 10:16 AM -----

● Rachael L. Sunbarger

05/14/2002 10:10:47 AM

Record Type: Record

To:

cc:

Subject: EVENT BACKGROUNDER: SIGNING OF HEMATOLOGICAL CANCER RESEARCH INVESTMENT AND EDUCATION ACT

THE WHITE HOUSE
Office of the Press Secretary

EVENT BACKGROUNDER
Signing of Hematological Cancer Research Investment and Education Act
Oval Office
May 14, 2002

BACKGROUND INFORMATION:

The President will sign S. 1094, a bill that creates a new law that increases research for awareness of leukemia, lymphoma, and multiple myeloma.

The Hematological Cancer Research Investment and Education Act authorizes the National Institutes of Health (NIH) and the National Cancer Institute (NCI) to spend funds to increase

research and education on blood cancers. The bill creates the “Bill Moakley Research Program” that directs the NIH and NCI to expand and identify research into blood cancers. It also creates the “Geraldine Ferraro Cancer Education Program” to increase public information about and awareness of these diseases.

ATTENDEES:

Senator Kay Bailey Hutchison

Senator Barbara Mikulski

Representative Phil Crane

Representative Jim McGovern

Elias Zerhouni, Director, National Institutes of Health

Andrew von Eschenbach, Director, National Cancer Institute

Geraldine Ferraro, Former Vice Presidential Candidate

Patricia Hamel, Niece of late-Representative Joe Moakley

###



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget Approval

Department of Health and Human Services Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell E. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".

The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,

Tommy G. Thompson

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
Subject: AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

THE PRESIDENT HAS SEEN
5-14-02

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education
Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget

Approval

Department of Health and Human Services

Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures

Bills Received at the White House

Date received and
notification to OMB: 5/6/2002
Last day for action: 5/17/2002

S.1094

Official Title	
An Act to amend the Public Health Service Act to provide for research, information, and education with respect to blood cancer.	521551

H.R.3525

An Act to enhance the border security of the United States,
and for other purposes.

521568

Bills Received at the White House

Date received and
notification to OMB: **5/8/2002**
Last day for action: **5/20/2002**

Official Title

One Hundred Seventh Congress
of the
United States of America

AT THE SECOND SESSION

*Begun and held at the City of Washington on Wednesday,
the twenty-third day of January, two thousand and two*

An Act

To amend the Public Health Service Act to provide for research, information, and education with respect to blood cancer.

*Be it enacted by the Senate and House of Representatives of
the United States of America in Congress assembled,*

SECTION 1. SHORT TITLE.

This Act may be cited as the "Hematological Cancer Research Investment and Education Act of 2002".

SEC. 2. FINDINGS.

Congress finds that:

(1) An estimated 109,500 people in the United States will be diagnosed with leukemia, lymphoma, and multiple myeloma in 2001.

(2) New cases of the blood cancers described in paragraph (1) account for 8.6 percent of new cancer cases.

(3) Those devastating blood cancers will cause the deaths of an estimated 60,300 persons in the United States in 2001. Every 9 minutes, a person in the United States dies from leukemia, lymphoma, or multiple myeloma.

(4) While less than 5 percent of Federal funds for cancer research are spent on those blood cancers, those blood cancers cause 11 percent of all cancer deaths in the United States.

(5) Increased Federal support of research into leukemia, lymphoma, and multiple myeloma has resulted and will continue to result in significant advances in the treatment, and ultimately the cure, of those blood cancers as well as other cancers.

SEC. 3. RESEARCH, INFORMATION, AND EDUCATION WITH RESPECT TO BLOOD CANCER.

Part C of title IV of the Public Health Service Act (42 U.S.C. 285 et seq.) is amended by inserting after section 419C the following:

"SEC. 417D. RESEARCH, INFORMATION, AND EDUCATION WITH RESPECT TO BLOOD CANCER.

"(a) JOE MOAKLEY RESEARCH EXCELLENCE PROGRAM.—

"(1) IN GENERAL.—The Director of NIH shall expand, intensify, and coordinate programs for the conduct and support of research with respect to blood cancer, and particularly with respect to leukemia, lymphoma, and multiple myeloma.

"(2) ADMINISTRATION.—The Director of NIH shall carry out this subsection through the Director of the National Cancer Institute and in collaboration with any other agencies that the Director determines to be appropriate.

“(3) AUTHORIZATION OF APPROPRIATIONS.—For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose.

“(b) GERALDINE FERRARO CANCER EDUCATION PROGRAM.—

“(1) IN GENERAL.—The Secretary shall direct the appropriate agency within the Department of Health and Human Services, in collaboration with the Director of NIH, to establish and carry out a program to provide information and education for patients and the general public with respect to blood cancer, and particularly with respect to the treatment of leukemia, lymphoma, and multiple myeloma.

“(2) ADMINISTRATION.—The Agency determined by the Secretary under paragraph (1) shall carry out this subsection in collaboration with private health organizations that have national education and patient assistance programs on blood-related cancers.

“(3) AUTHORIZATION OF APPROPRIATIONS.—For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose.”.

Speaker of the House of Representatives.

*Vice President of the United States and
President of the Senate.*

WHITE HOUSE STAFFING MEMORANDUM

Date: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT <i>NC</i>	☒	☐	HUBBARD	☐	☐
CARD <i>OK</i>	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN <i>✓</i>	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER <i>recommends approval</i>	☒	☐
CALIO <i>OK</i>	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES <i>N/C</i>	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

Harriet E. Miers
 Assistant to the President
 and Staff Secretary
 Ext. 62702

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE: _____

Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget

Approval

Department of Health and Human Services

Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell E. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".

The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,

Tommy G. Thompson

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget	Approval
Department of Health and Human Services	Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell F. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".

The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,

Tommy G. Thompson



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education
Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget	Approval
Department of Health and Human Services	Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget

Approval

Department of Health and Human Services

Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures

 *** TX REPORT ***

TRANSMISSION OK

TX/RX NO 3716
 CONNECTION TEL 66212
 CONNECTION ID
 ST. TIME 05/09 12:20
 USAGE T 01'12
 PGS. SENT 4
 RESULT OK

SS/ RM NO. _____

WHITE HOUSE STAFFING MEMORANDUM

Date: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AM

ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
 Subject: AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: **ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
AND EDUCATION ACT OF 2002**

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702

 *** TX REPORT ***

TRANSMISSION OK

TX/RX NO	3717	
CONNECTION TEL		66021
CONNECTION ID		
ST. TIME	05/09 12:22	
USAGE T	01'12	
PGS. SENT	4	
RESULT	OK	

SS/ RM NO. _____

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AM

ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
 Subject: AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY _____

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702

 *** TX REPORT ***

TRANSMISSION OK

TX/RX NO 3718
 CONNECTION TEL 51005
 CONNECTION ID
 ST. TIME 05/09 12:32
 USAGE T 01'12
 PGS. SENT 4
 RESULT OK

SS/ RM NO. _____

WHITE HOUSE STAFFING MEMORANDUM

Date: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AM

ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
 Subject: AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☒	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☒	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget

Approval

Department of Health and Human Services

Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell E. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".

The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,

Tommy G. Thompson

WHITE HOUSE STAFFING MEMORANDUM


Date: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐		☐	☐
HAWKINS	☒	☐		☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:



Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget

Approval

Department of Health and Human Services

Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell E. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".


The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,



Tommy G. Thompson

WHITE HOUSE STAFFING MEMORANDUM

02 MAY 9 PM:00

Date: 5-9-02ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AM

ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
 Subject: AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY
 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE: _____

Harriet E. Miers
 Assistant to the President
 and Staff Secretary
 Ext. 62702



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education
Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget

Approval

Department of Health and Human Services

Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell E. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".


The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,


Tommy G. Thompson

SS/ RM NO.

WHITE HOUSE STAFFING MEMORANDUM

*RACHEL*Date: 5-9-02ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AM

ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
 Subject: AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES 	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

No Comments

RESPONSE:

Harriet E. Miers
 Assistant to the President
 and Staff Secretary
 Ext. 62702



OFFICE OF THE VICE PRESIDENT
WASHINGTON

'02 MAY 10 AM 9:37

May 10, 2002

MEMORANDUM FOR JIM JUKES
ASSISTANT DIRECTOR, OMB

FROM: **JONATHAN BURKS** 
DEPUTY STAFF SECRETARY TO THE VICE PRESIDENT

SUBJECT: **Enrolled Bill S. 1094 – Hematological Cancer**
Research Investment and Education Act of 2002

The Office of the Vice President has reviewed the above-referenced enrolled bill memorandum and has no comments.

cc: **Harriet Miers**
Staff Secretary

05/09/02 THU 12:22 FAX

0001

SS/ RM NO. _____

WHITE HOUSE STAFFING MEMORANDUMDate: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

OSTP RECOMMENDS APPROVAL

Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702

62215

WHITE HOUSE STAFFING MEMORANDUM

Date: 5-9-02 ACTION / CONCURRENCE / COMMENT DUE BY: 5-10-02 10:00 AMSubject: ENROLLED BILL S. 1094 - HEMATOLOGICAL CANCER RESEARCH INVESTMENT
AND EDUCATION ACT OF 2002

	ACTION	FYI		ACTION	FYI
VICE PRESIDENT	☒	☐	HUBBARD	☐	☐
CARD	☒	☐	HUGHES	☒	☐
BARTLETT	☒	☐	IRASTORZA	☐	☐
BLAKEMAN	☐	☐	JOHNSON	☐	☐
BOLTEN	☒	☐	LINDSEY	☒	☐
BRIDGELAND	☐	☐	MARBURGER	☒	☐
CALIO _____	☒	☐	MIERS	☐	☐
CONNAUGHTON	☐	☐	RICE	☐	☐
DANIELS	☐	☒	RIDGE	☐	☐
FLEISCHER	☒	☐	ROVE	☒	☐
GERSON	☐	☐	SPELLINGS	☒	☐
GONZALES	☒	☐	CLERK	☐	☒
HAGIN	☐	☐	_____	☐	☐
HAWKINS	☒	☐	_____	☐	☐

REMARKS:

PLEASE FORWARD YOUR COMMENTS TO JIM JUKES, EXTENSION 54864/FAX 56148, BY 10:00 AM TOMORROW AND SEND A COPY TO THE STAFF SECRETARY. THANK YOU.

RESPONSE:

*Legislative Affairs (Howard) - ok**THERE IS A PULL SIGNING CRABBY
SCHEDULED FOR THURSDAY.*Harriet E. Miers
Assistant to the President
and Staff Secretary
Ext. 62702



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

THE DIRECTOR

May 9, 2002

MEMORANDUM FOR THE PRESIDENT

SUBJECT: Enrolled Bill S. 1094 - Hematological Cancer Research Investment and Education Act of 2002
Sponsors - Sen. Hutchison (R) TX and six cosponsors

Last Day for Action

May 17, 2002 - Friday

Purpose

Authorizes appropriations for blood cancer research and a related education program at the Department of Health and Human Services (HHS).

Agency Recommendations

Office of Management and Budget	Approval
Department of Health and Human Services	Approval

Discussion

S. 1094 is designed to expand and coordinate the National Institutes of Health's (NIH) research on blood cancer and to establish an educational program on blood cancer.

S. 1094 would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for NIH to expand, intensify, and coordinate its blood cancer research programs, especially those affecting leukemia, lymphoma, and multiple myeloma. This expanded blood cancer research effort would be known as the "Joe Moakley Research Excellence Program," named after the former congressman (D-MA), who died of leukemia on May 31, 2001.


S. 1094 also would authorize appropriations of such sums as may be necessary for FY 2002 and each subsequent fiscal year for HHS, in collaboration with NIH and certain private health organizations, to establish and implement a program to provide information and education for patients and the general public on blood cancer, particularly leukemia, lymphoma, and multiple myeloma. The new education program would be called the "Geraldine Ferraro Cancer Education Program," named after the former congresswoman (D-NY) and vice-presidential candidate, who suffers from multiple myeloma.

The authorizations of appropriations contained in S. 1094 would be in addition to other authorizations of appropriations available to HHS for blood research and cancer education programs.

Conclusion and Recommendations

HHS recommends approval of S. 1094. In its views letter on the enrolled bill, the Department states that "[t]he programs authorized by the bill fit the missions of HHS agencies" and "[t]he bill does not present any difficulties in terms of anticipated implementation."

We join HHS in recommending approval of S. 1094, which passed the Senate by unanimous consent and the House by voice vote.



Mitchell E. Daniels, Jr.
Director

Enclosures



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

May 8, 2002

The Honorable Mitchell E. Daniels, Jr.
Director, Office of Management
and Budget
Washington, D.C. 20503

Dear Mr. Daniels:

This responds to your request for the views of the Department of Health and Human Services (HHS) on S. 1094, an enrolled bill entitled the "Hematological Cancer Research Investment and Education Act of 2001".

The bill would amend the Public Health Service Act to authorize the National Institutes of Health (NIH) to expand research on blood cancer (leukemia, lymphomas, multiple myelomas, and others) and to authorize HHS to establish a program of education for patients and the public about these diseases. It would authorize such sums as may be necessary for each program, in addition to other authorizations available for these purposes.

Blood cancers are a substantial public health problem. Almost 700,000 Americans are currently living with these diseases. While survival rates are increasing, the five-year survival rate for leukemia is still only 46%, and that for multiple myeloma only 28%, and leukemia still causes more childhood deaths in the United States than any other disease. There has been much promising research in this area, including development of the recently-approved drug Gleevec based on genetic analysis of chronic myeloid leukemia.

The programs authorized by the bill fit the missions of HHS agencies. Last year, the National Cancer Institute (NCI) released a report on research into these diseases, describing its current research portfolio and identifying gap areas where additional research opportunities exist. The education and information program is appropriate for HHS agencies that have responsibilities in this area, including NCI and the Centers for Disease Control and Prevention. The bill does not present any difficulties in terms of anticipated implementation.

We therefore recommend that the President approve the bill.

Sincerely,

Tommy G. Thompson